The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2019 | Axi-cel in older patients: data from ZUMA-1 and clinical use
Sattva Neelapu, MD, University of Texas MD Anderson Cancer Center, Houston, TX, explains the latest results for the use of axicabtagene ciloleucel in older large B-cell lymphoma patients. Dr Neelapu discusses data from both ZUMA-1 (NCT02348216) and real world data from the US Lymphoma CAR-T Consortium. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
